Strategic partnership Recent collaboration with High Q Technologies to expand global access to quantum-enabled EPR spectroscopy presents a prime entry point for co-selling advanced spectroscopy capabilities and cross-selling Cryo-EM and membrane protein services to shared customers.

Advanced platform expansion Launch of Cryo-EM platform and membrane protein screening capabilities signals a broadening service portfolio, creating upsell opportunities for customers needing end-to-end structure determination from gene to structure across challenging targets like GPCRs, ion channels, and viral proteins.

Diversified services Introduction of exosome analysis, Mempro CRAL-TRIO protein production, and hydrophobic interaction chromatography services provides multiple entry points for biotech and pharma clients seeking comprehensive structural biology workflows and purification solutions.

Competitive pricing Positioning around cost-effective, short-turnaround pipelines can be leveraged to win price-conscious academia and startups, especially when offering bundled services (gene-to-structure) and rapid pilots to de-risk early-stage projects.

Growth signals Active ongoing product and platform development with strategic press coverage indicates market adoption and momentum, creating opportunities for channel partnerships, sponsored research, and early-access deals with larger biotech players seeking scalable structural biology capabilities.